SHPHF (Sihuan Pharmaceutical Holdings Group) Risk Assessment

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHPHF Sihuan Pharmaceutical Holdings Group Ltd SHPHF
52 GF Score
Price $0.12
GF Value $0.17
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Sihuan Pharmaceutical Holdings Group Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Sihuan Pharmaceutical Holdings Group is: Moderate Risk: Sensitive, better choose undervalued stock.

Sihuan Pharmaceutical Holdings Group  (OTCPK:SHPHF) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Sihuan Pharmaceutical Holdings Group Risk Assessment Related Terms

SHPHF vs ZTS, UTHR: Risk Assessment Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Sihuan Pharmaceutical Holdings Group's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sihuan Pharmaceutical Holdings Group Risk Assessment vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sihuan Pharmaceutical Holdings Group's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Sihuan Pharmaceutical Holdings Group's Risk Assessment falls into.


SHPHF
52GF Score
Sihuan Pharmaceutical Holdings Group Ltd SHPHF
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Sihuan Pharmaceutical Holdings Group (SHPHF) Overvalued in 2026?

Based on GuruFocus' analysis, Sihuan Pharmaceutical Holdings Group stock appears to be undervalued. The current stock price of $0.12 is trading 29.4% below its estimated GF Value™ of $0.17. GuruFocus considers Sihuan Pharmaceutical Holdings Group to be Modestly Undervalued.

Key valuation signals for SHPHF:

  • Risk Assessment:
  • GF Value™: $0.17 vs. price of $0.12 (29.4% below fair value)
  • GF Score™: 52/100 with 4 warning signs

No single metric tells the full story. See the SHPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sihuan Pharmaceutical Holdings Group Business Description

Other Exchanges 00460:Hong KongTEL1:Germany
Address 1 Harbour Road, Convention Plaza, Room 4905, Office Tower, Wanchai, HKG
Sihuan Pharmaceutical Holdings Group Ltd is an investment holding company. Along with its subsidiaries, the company is engaged in the research & development and the manufacture & sale of pharmaceutical products. Its portfolio comprises products for diseases related to the cardio-cerebral vascular (CCV) system, Respiratory, Neurology, and others. The group has three reportable segments: the medical aesthetic products segment, including the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skincare, and others; the innovative medicine and other medicine segment; and the generic medicine segment, which generates key revenue. Geographically, the company generates a majority of its revenue from Mainland China and the rest from the United States.
52GF Score

Get the complete analysis for SHPHF

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.12
Price
$0.17
GF Value